Friday 6 November 2026 Export LKFT’s income statement to Excel — free account

Lakefront Biotherapeutics - Sponsored ADR

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue: −95.4%
EPS: +198.9%
Free cash flow: +18.2%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

33.47 0.09 −0.27%

Follow LKFT

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −15.3×
Dividend yield: —
F-score: 6/9
Altman Z: 8.43
Beneish M: 0.34
Dividend safety: n/a

Overview

Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a P/B ratio of 0.6×. Over the past ten years it has ranged from 0.0× (March 2015) to 8.0× (July 2019); the current reading is higher than 13% of that period. That is below the Biotechnology industry median of 2.0× and below the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LKFT/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Lakefront Biotherapeutics - Sponsored ADR P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LKFT/metrics/pb-ratio">Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	0.8×	30.82%
FY2024	0.6×	(39.74%)
FY2023	1.0×	(12.80%)
FY2022	1.1×	(5.19%)
FY2021	1.2×	(45.32%)
FY2020	2.1×	(42.93%)
FY2019	3.7×	10.98%
FY2018	3.3×	(7.06%)
FY2017	3.6×	(0.19%)
FY2016	3.6×	(35.05%)

Period	P/B ratio	Change
Mar 2026	0.5×	(9.14%)
Mar 2025	0.6×	(16.06%)
Mar 2024	0.7×	(14.35%)
Sep 2023	0.8×	(16.72%)
28 more quarters	Free account

Against its own ten years

Low 0.0× High 8.0×

Ten-year median 1.8×

Current reading's percentile 12

Company	P/B ratio
BHVN Biohaven Ltd. compare	n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR	0.6×
AUPH Aurinia Pharmaceuticals Inc compare	3.3×
IMNM Immunome, Inc. compare	3.9×
VERA Vera Therapeutics, Inc. compare	5.3×
SEPN Septerna, Inc. compare	5.6×
VCEL Vericel Corporation compare	6.8×
PVLA Palvella Therapeutics, Inc. compare	10.4×
ZYME Zymeworks Inc. compare	26.2×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on LKFT

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on LKFT

Stockrow Weekly